Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace

NCT00229658 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00229658
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00229658 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
September 30, 2005
Completion date
May 31, 2008
Enrollment
1,297 (actual)
Sites
107

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 diabetes mellitus, type 2 diabetes mellitus